Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899142 | 0.85 | GAA (0.47) | LMNASMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL6069272 | 0.83 | NPC1 (0.55) | NPC1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5774873 | 0.82 | LMNA (0.54) | NPC1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12691771 | 0.81 | HSD17B10 (0.48) | LMNASMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL30395326 | 0.79 | GPBAR1 (0.60) | NPC1LMNAKMT2AMEN1GAA | |
| SCHEMBL3826089 | 0.79 | GPBAR1 (0.60) | NPC1LMNAKMT2AMEN1GAA | |
| SCHEMBL6695996 | 0.77 | GPBAR1 (0.49) | LMNASMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL12544125 | 0.77 | GPBAR1 (0.49) | LMNASMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL30684510 | 0.77 | GABRA5 (0.54) | LMNASMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL12543755 | 0.77 | GABRA5 (0.54) | LMNASMN1; SMN2KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037921-B2 | Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1 | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1392702-B1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | BONJOUKLIAN ROSANNE (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1392702-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002081482-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | ABCC1, ABCB1, ABCB11 | NPC1 17/4885LMNA 2127/4885SMN1; SMN2 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.